Home

Articles from Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company’s common stock at an exercise price per share of $13.33, which was the closing price on January 23, 2024, and restricted stock units to acquire a total of 16,000 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · January 24, 2025
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus’s responsibilities will include oversight of Arcus’s clinical development organization and its late-stage portfolio, currently including four ongoing registrational Phase 3 studies, the first of which, STAR-221, is expected to read out next year. Arcus plans to initiate a fifth registrational Phase 3 study, PEAK-1, in the first half of 2025, to evaluate its HIF-2a inhibitor casdatifan plus cabozantinib in people with clear-cell renal cell carcinoma (ccRCC) who have progressed on immunotherapy. Dr. Markus’s extensive late-stage development experience will be essential as he leads Arcus’s strategy and efforts to fully leverage the opportunities in Arcus’s portfolio.
By Arcus Biosciences · Via Business Wire · January 21, 2025
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 66,900 shares of the Company’s common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024, and restricted stock units to acquire a total of 33,450 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · December 24, 2024
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT.
By Arcus Biosciences · Via Business Wire · December 19, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 7,400 shares of the Company’s common stock at an exercise price per share of $17.47 which was the closing price on December 9, 2024, and restricted stock units to acquire a total of 3,700 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · December 10, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 10,000 shares of the Company’s common stock at an exercise price per share of $14.56, which was the closing price on November 25, 2024, and restricted stock units to acquire a total of 5,000 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · December 3, 2024
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December:
By Arcus Biosciences · Via Business Wire · November 19, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company’s common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · November 12, 2024
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers.
By Arcus Biosciences · Via Business Wire · November 6, 2024
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with front-line locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. This study was conducted in partnership with Gilead Sciences. These results will be presented on November 8 in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting by Melissa L. Johnson, M.D., Director of the Lung Cancer Research Program, Sarah Cannon Research Institute, and investigator for the ARC-10 study.
By Arcus Biosciences · Via Business Wire · November 5, 2024
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024.
By Arcus Biosciences · Via Business Wire · October 30, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company’s common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and restricted stock units to acquire a total of 14,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · October 24, 2024
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
By Arcus Biosciences · Via Business Wire · October 24, 2024
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended September 30th, 2024.
By Arcus Biosciences · Via Business Wire · October 22, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company’s common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and restricted stock units to acquire a total of 12,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · October 9, 2024
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The data being presented include a growing body of evidence supporting the potential of casdatifan as a best-in-class HIF-2a inhibitor for the treatment of ccRCC.
By Arcus Biosciences · Via Business Wire · October 9, 2024
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus’s investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca’s investigational PD-1/CTLA-4 bispecific antibody, in patients with ccRCC.
By Arcus Biosciences · Via Business Wire · October 2, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 38,600 shares of the Company’s common stock at an exercise price per share of $15.71, which was the closing price on September 23, 2024, and restricted stock units to acquire a total of 19,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · September 24, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 27,800 shares of the Company’s common stock at an exercise price per share of $16.31, which was the closing price on September 9, 2024, and restricted stock units to acquire a total of 13,900 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · September 10, 2024
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. NYSE: HTGCNYSEHTGC)
By Arcus Biosciences · Via Business Wire · August 27, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company’s common stock at an exercise price per share of $18.01, which was the closing price on August 23, 2024, and restricted stock units to acquire a total of 10,550 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · August 26, 2024
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:
By Arcus Biosciences · Via Business Wire · August 21, 2024
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a, AXL and PD-1 – across multiple common cancers.
By Arcus Biosciences · Via Business Wire · August 8, 2024
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended June 30th, 2024.
By Arcus Biosciences · Via Business Wire · July 25, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 25,200 shares of the Company’s common stock at an exercise price per share of $13.84, which was the closing price on July 8, 2024, and restricted stock units to acquire a total of 12,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · July 9, 2024
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
Arcus Biosciences, Inc. (NYSERCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program.
By Arcus Biosciences · Via Business Wire · July 8, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company’s common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and restricted stock units to acquire a total of 1,750 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · June 25, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company’s common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and restricted stock units to acquire a total of 18,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · June 11, 2024
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
By Arcus Biosciences · Via Business Wire · June 10, 2024
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Wednesday, June 12th, 2024 at 10:00am ET.
By Arcus Biosciences · Via Business Wire · June 6, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company’s common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and restricted stock units to acquire a total of 8,150 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · May 24, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company’s common stock at an exercise price per share of $15.26, which was the closing price on May 8, 2024, and restricted stock units to acquire a total of 70,555 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · May 9, 2024
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a, AXL and PD-1 – across multiple common cancers.
By Arcus Biosciences · Via Business Wire · May 8, 2024
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV. The fireside chat will take place on Thursday, May 16th, 2024 at 10:00am PT.
By Arcus Biosciences · Via Business Wire · May 2, 2024
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024. The selected abstracts presented in partnership with Gilead Sciences provide strong support for the companies’ portfolio of investigational medicines across multiple types of cancer, including lung, upper GI and colorectal cancer.
By Arcus Biosciences · Via Business Wire · April 24, 2024
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended March 31st, 2024.
By Arcus Biosciences · Via Business Wire · April 23, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 45,000 shares of the Company’s common stock at an exercise price per share of $16.97, which was the closing price on April 8, 2024, and restricted stock units to acquire a total of 22,500 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · April 9, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $16.47, which was the closing price on March 25, 2024, and restricted stock units to acquire a total of 9,200 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · March 26, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 13,800 shares of the Company’s common stock at an exercise price per share of $17.99, which was the closing price on March 8, 2024, and restricted stock units to acquire a total of 6,900 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · March 11, 2024
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March:
By Arcus Biosciences · Via Business Wire · February 28, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.53, which was the closing price on February 26, 2024, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · February 27, 2024
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a, AXL and PD-1 – across multiple common cancers.
By Arcus Biosciences · Via Business Wire · February 21, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 71,900 shares of the Company’s common stock at an exercise price per share of $15.20, which was the closing price on February 8, 2024, and restricted stock units to acquire a total of 35,950 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · February 9, 2024
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company’s financial results for the quarter and year ended December 31st, 2023.
By Arcus Biosciences · Via Business Wire · February 7, 2024
Gilead and Arcus Announce Amended Collaboration and Equity Investment
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSERCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three. The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.
By Arcus Biosciences · Via Business Wire · January 29, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 76,700 shares of the Company’s common stock at an exercise price per share of $15.26, which was the closing price on January 25, 2024, and restricted stock units to acquire a total of 38,350 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · January 26, 2024
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
Arcus Biosciences, Inc. (NYSERCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. ARC-8 is the study of quemliclustat, an investigational small molecule CD73 inhibitor, plus chemotherapy with or without zimberelimab, an investigational anti-PD-1 antibody, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). The results will be presented during the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
By Arcus Biosciences · Via Business Wire · January 16, 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and restricted stock units to acquire a total of 9,800 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · December 11, 2023
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSERCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis is sponsoring STELLAR-009, and Arcus is co-funding the study and providing AB521 for use in the trial. Patient enrollment for STELLAR-009 is expected to begin before the end of 2023.
By Arcus Biosciences · Via Business Wire · December 4, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $14.06, which was the closing price on November 24, 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · November 27, 2023
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL. The fireside chat will take place on Tuesday, November 28th, 2023 at 7:55am ET.
By Arcus Biosciences · Via Business Wire · November 14, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price per share of $16.01, which was the closing price on November 8, 2023, and restricted stock units to acquire a total of 15,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · November 13, 2023
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.
By Arcus Biosciences · Via Business Wire · November 7, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 4,800 shares of the Company’s common stock at an exercise price per share of $16.18, which was the closing price on October 23, 2023, and restricted stock units to acquire a total of 2,400 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · October 24, 2023
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
Arcus Biosciences, Inc. (NYSERCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series on November 7, 2023. EDGE-Gastric (also known as ARC-21), a collaboration between Arcus and Gilead Sciences, is a Phase 2 platform study evaluating various combinations of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, and zimberelimab, an anti-PD-1 antibody, in patients with locally advanced unresectable or metastatic gastric (G), gastroesophageal junction (GEJ) or esophageal (E) adenocarcinoma. Cohort A1 evaluates the combination of domvanalimab plus zimberelimab and chemotherapy given as an initial treatment in approximately 40 patients.
By Arcus Biosciences · Via Business Wire · October 17, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 34,300 shares of the Company’s common stock at an exercise price per share of $16.41, which was the closing price on October 9, 2023, and restricted stock units to acquire a total of 17,150 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · October 10, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 33,200 shares of the Company’s common stock at an exercise price per share of $18.66, which was the closing price on September 25, 2023, and restricted stock units to acquire a total of 16,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · September 26, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $21.38, which was the closing price on September 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · September 11, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 14,600 shares of the Company’s common stock at an exercise price per share of $23.03, which was the closing price on August 23, 2023, and restricted stock units to acquire a total of 7,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · August 24, 2023
Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:
By Arcus Biosciences · Via Business Wire · August 23, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $18.44, which was the closing price on August 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · August 9, 2023
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.
By Arcus Biosciences · Via Business Wire · August 7, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $19.50, which was the closing price on July 24, 2023, and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · July 25, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an exercise price per share of $21.88, which was the closing price on July 10, 2023, and restricted stock units to acquire a total of 10,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · July 11, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 11,800 shares of the Company’s common stock at an exercise price per share of $19.24, which was the closing price on June 23, 2023, and restricted stock units to acquire a total of 5,900 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · June 26, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 11,600 shares of the Company’s common stock at an exercise price per share of $21.64, which was the closing price on June 8, 2023, and restricted stock units to acquire a total of 5,800 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · June 9, 2023
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California. The fireside chat will take place on Tuesday, June 13th, 2023 at 4 p.m. PT.
By Arcus Biosciences · Via Business Wire · May 30, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 53,800 shares of the Company’s common stock at an exercise price per share of $18.05, which was the closing price on May 23, 2023, and restricted stock units to acquire a total of 26,900 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · May 24, 2023
Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2023. The selected abstracts presented in partnership with Gilead Sciences highlight the company’s expanding portfolio of investigational medicines and late-stage studies across multiple types of cancer, including lung, upper GI and kidney cancer.
By Arcus Biosciences · Via Business Wire · May 17, 2023
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSERCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into inflammation.
By Arcus Biosciences · Via Business Wire · May 15, 2023
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.
By Arcus Biosciences · Via Business Wire · May 9, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,200 shares of the Company’s common stock at an exercise price per share of $19.85, which was the closing price on May 8, 2023, and restricted stock units to acquire a total of 5,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · May 8, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.31, which was the closing price on April 24, 2023, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · April 25, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 34,000 shares of the Company’s common stock at an exercise price per share of $17.36, which was the closing price on April 10, 2023, and restricted stock units to acquire a total of 15,200 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · April 11, 2023
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 66,200 shares of the Company’s common stock at an exercise price per share of $17.78, which was the closing price on March 8, 2023 and restricted stock units to acquire a total of 33,100 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
By Arcus Biosciences · Via Business Wire · March 9, 2023